Non-thermal Pulsed Radio Frequency for Pain Amelioration in Adults With Knee Osteoarthritis: A Double-blind, Randomized, Sham-controlled Trial
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Knee Osteoarthritis
- Sponsor
- Amp Orthopedics, Inc.
- Enrollment
- 45
- Locations
- 1
- Primary Endpoint
- A comparison of changes in VAS pain scores at 4 weeks over baseline.
- Status
- Terminated
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to determine the effectiveness of non-thermal Pulsed Radio Frequency (PRF) treatment with the Ivivi SofPulse for amelioration of knee pain in patients with mild to moderate Osteoarthritis and to determine the duration of clinical benefit following discontinuation of treatment.
Detailed Description
This prospective, double-blind, randomized, sham-controlled clinical trial will investigate the effectiveness of PRF using the Ivivi SofPulse on knee pain severity in adults with mild to moderate knee OA. Potential subjects will complete questions related to medical history, inclusion / exclusion criteria, and OA symptom severity. Knee radiographs will be evaluated by the Principal Investigator (PI) or co-investigator for determination of knee OA severity based on the Kellgren/Lawrence criteria. Eligible subjects will enter a 1-week run-in period. After successful completion of the run-in period, subjects will be randomized to PRF treatment twice a day (Active) or sham treatment twice a day (Sham). All subjects will be followed for 4 weeks for purposes of the primary endpoint evaluation. Thereafter, the subjects initially allocated to Active will be equally allocated to Active or Sham and will be followed through 26 or 8 weeks, respectively. The subjects originally assigned to Sham will maintain this treatment regimen through 26 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 40 to 80 years
- •Bilateral weight-bearing anteroposterior x-ray of each knee taken within the last 12 months and radiographs submitted to the Principal Investigator for evaluation
- •Radiographic evidence of mild to moderate (Kellgren/Lawrence grade 2 or 3) OA in at least one knee based on a weight-bearing anteroposterior x-ray taken within the last 12 months
- •Self-reported persistent knee pain severity of 4.0 to 8.0 cm on a 10 cm VAS for most days in the previous 2 months in at least one knee, with grade 2 or 3 OA
- •Able to read and complete English-language surveys
- •Daily access to the internet
- •Ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects
- •Consent to the study and willing to comply with study methods
Exclusion Criteria
- •Subjects who have any implanted metallic leads, wires, or systems (e.g. pacemaker, implantable cardioverterdefibrillator)
- •Self-reported persistent knee pain severity \> 8.0 cm on a 10 cm VAS in either knee for most days in the previous 2 months
- •Radiographic evidence of severe (Kellgren/Lawrence grade 4) OA in either knee based on a weight-bearing anteroposterior x-ray taken within the last 12 months
- •Self-reported diagnosis of autoimmune or inflammatory arthritis (e.g. Rheumatoid Arthritis, Lupus, etc.)
- •More than 8 days of narcotic pain medication in the last 30 days
- •Joint surgery, tidal lavage, or arthroscopy of either knee in the past 6 months
- •Intra-articular corticosteroid or hyaluronic acid injections of either knee in the past 6 months
- •Oral prednisone use in the past 30 days
- •Participation in any clinical trial in the past 30 days
- •Knee OA associated with worker's compensation or accident litigation
Outcomes
Primary Outcomes
A comparison of changes in VAS pain scores at 4 weeks over baseline.
Time Frame: Four weeks
Comparison of changes in "current" knee pain severity at 4 wks over baseline. Between-group difference of at least 25 percentage points considered clinically significant. "Current" knee pain severity assessed on a 10 cm visual analogue scale, 0 (no pain) and 10 (pain as bad as it can be). The knee that meets radiographic criteria for mild or moderate knee OA and has the highest knee pain severity based on the average daily severity score during the 1-wk run-in period will be selected for the primary endpoint analysis.
Secondary Outcomes
- Change in knee pain severity and duration of clinical benefit following treatment.(Four weeks)
- EuroQol EQ-5D(Four weeks)
- OMERACT-OARSI Responder Rate(Four weeks)
- Adverse events(Four weeks)
- Treatment compliance(Four weeks)